Close this search box.

ICER’s Respiratory Review: Clinician Voices for Patient Access

Who decides which medications are available to the millions of Americans living with asthma?

Increasingly, questions of access are informed by the Institute for Clinical and Economic Review, or ICER. The health economics organization uses clinical trials data and available pricing information to consider whether a drug is worth its cost.

Now, ICER is reviewing a new treatment for asthma. ICER’s upcoming review will examine a new biologic medication, tezepelumab, designed to significantly reduce severe asthma attacks.

ICER plans to compare tezepelumab to:
• Dupilumab
• Omalizumab
• Usual care (estimated by placebo arms of clinical trials) in all patients with severe asthma

Get Involved

ICER’s 2021 review will consider the cost-effectiveness of tezepelumab for adults and adolescents with severe asthma.

ICER Submission Guidelines 

(It is very important you follow these guidelines so that your comments will be accepted.)

  • Your letter must be submitted as a Word document (.doc) and sent via email as an attachment. PDFs are not accepted. ICER will not accept your letter if it is typed in the body of the email. 
  • Your letter cannot exceed 3 pages.
  • Your letter must be typed in Word, using Times New Roman font and 12-point font size.
  • In the subject line of your email please write: PUBLIC COMMENT FOR REVIEW OF SEVERE ASTHMA TREATMENT
  • Your email with your letter attached as a Word document, should be sent to [email protected] between September 16 and October 14, 2021 at 5pm ET.  

For questions or to get involved email Casey McPherson at [email protected].

Featured Resources

Why ICER Matters to Clinicians & Patients with Severe Asthma

Clinicians and patients should tell ICER what matters to them.

View Infographic >

ICER’s Respiratory Review: Clinician Voices for Patient Access

This webinar covers how ICER's current review will impact patients' ability to access the care they need.

Watch Webinar >

Elevating the Voices of Severe Asthma: ICER Toolkit

This toolkit provides the information you need to bring your voice, expertise and insights to inform ICER’s decision.

Read More >

AAFA: Asthma Disparities in America

In the United States, the burden of asthma falls disproportionately on Black, Hispanic and American Indian and Alaska Native populations. Decades of extensive research and public health data identified disparities in asthma prevalence, mortality and health care utilization along racial and ethnic lines.

Read More >

AAFA: My Life With Asthma Survey Overview

For many years, asthma has been thought of as a single disease. But new studies show asthma is a chronic condition that can be different for each person. This means there is no “one size fits all” approach to managing asthma.

Read More >

AAN: Become a Patient Advocate

When we work together, we form a strong, collective voice to inform and influence public policy. There are opportunities on many levels. No legislative experience is needed – we provide the tools you need.

Learn More >

Patient-Centered Asthma Care

Far too often, asthma patients are subjected to insurance companies’ “one-size-fits-all” approach. Patients must be able to decide with their health care providers which treatment option helps them manage their asthma – and reclaim their day-to-day lives.

Watch Video >

Why Health Care Providers Should Care About ICER

ICER's value assessments can make it difficult, if not impossible, for patients to get the medicine they need.

Watch Video >

What's Wrong with ICER?

Sometimes economists can have more control than your doctor about whether you get the medicine that treats your condition.

Watch Video >

ICER Crosses the Center Line

The admonition to the Institute for Clinical and Economic Review’s Beacon Hill economists should be quite simple: “Stay in your lane.”

Read More >